assess the safety and efficacy of csa ophthalmic gel in subjects with dry eye

Conditions: Dry Eye

Summary: the purpose of this study is to explore the efficacy and safety of csa ophthalmic gel in the treatment of moderate to severe tear deficiency dry eye with different dosage, frequency and concentration, and to preliminarily determine the optimal dosage, frequency and concentration, so as to provide a theoretical basis for the design of follow-up clinical studies.

a multicenter, randomized, single-blind, positive controlled exploratory study will be conducted with cyclosporine a ophthalmic emulsion as the control drug. the experimental drugs were divided into three groups: treatment group a: csa eye gel: 0.3 g: 0.15 mg, once daily； treatment group b: csa eye gel: 0.3 g: 0.15 mg, twice daily, interval of about 12 hours； treatment group c: csa eye gel: 0.3 g: 0.3 mg, once daily. one drop into each eye when you use it. control group: csa emulsion: 0.4 ml: 0.2 mg. one drop into the eye, 2 times daily with an interval for 12 hours.

Eligibility criteria:
inclusion criteria: 1. age ≥18, both male and female; 2. pregnancy tests were negative for women of childbearing age and contraceptive measures (including abstinence, intrauterine devices, diaphragms and spermicides) were taken during the trial. men are willing to use approved contraceptive methods (possibly using condoms and spermicides or oral contraceptives, implants or injections of contraceptives, intrauterine devices, diaphragms and spermicides) or sexual partner infertility; 3. according to the symptoms and signs and ophthalmologic examinations, the patients were diagnosed as moderate to severe dry eye; 1. eds score is more than 40 points; 2. but is less than 10 s; 3. schirmer test result is less than 10mm/5 min; 4. in any area, corneal fluorescein staining was more than 2 points. 4. the anatomy of the eyelids is normal and has normal blinking function; 5. patients with newly diagnosed dry eye disease, or who are undergoing dry eye treatment, voluntarily discontinue treatment within 72 hours of entering the screening period; 6. ability and willingness to participate in all research assessments and all planned visits during the pilot period in accordance with the programme requirements; 7. agree to participate in the study and voluntarily sign informed consent. exclusion criteria: 1. allergy to csa, fluorescein or any component of the drug is known; 2. severe dry eye patients requiring surgical treatment; 3. glaucoma patients; 4. unwilling to avoid wearing contact lenses; 5. within 12 months prior to the start of the study, intraocular surgery or internal surgery was necessary; 6. eyelid surgery was performed within 6 months prior to the start of the study, or dry eye secondary to surgery; 7. those who had undergone corneal refractive surgery or keratoplasty; 8. congenital lacrimal gland or meibomian gland deficiency or lacrimal gland obstructive diseases; 9. systemic inflammation or active eye infection and blepharitis; 10. patients with ocular cicatricial pemphigoid, obvious conjunctival scar, ocular chemical burn and neurotrophic keratoconjunctivitis; 11. who suffered from ocular malignancies; 12. no other eye drops could be stopped during the study period; 13. systemic or uncontrollable disorders that affect the collection of research parameters or patient compliance, such as severe cardiopulmonary disease, uncontrollable hypertension and diabetes; 14. with history of central nervous system disease or epilepsy, and / or mental disorder; 15. pregnant women and lactating women, or women of childbearing age, do not adopt effective contraceptive measures; 16. participated in other clinical trials or participated in other clinical trials within 1 months before the election; 17. systemic or topical cyclosporine drugs within 3 months; 18. patients who were not considered suitable for the study, including those who were unable or unwilling to comply with the protocol requirements.